Possible correlations between symptoms suggesting gastroparesis and dyskinesias in advanced Parkinson’s disease
Objective: The objective was to describe the spectrum of gastrointestinal complaints in a large cohort of patients with advanced Parkinson’s Disease (APD), who were repeatedly…Psychometric properties of clinical indicators of device-aided therapy eligibility among Parkinson’s disease patients: Real-world data from 6 countries
Objective: Evaluate the performance of clinical indicators for Device-aided Therapy (DAT) eligibility in real-world setting. Background: Timely initiation of appropriate DAT may improve quality of…Maladaptive motor cortex plasticity off medication in Parkinson’s disease patients with levodopa-induced dyskinesias
Objective: To test the hypothesis that motor cortex plasticity is maladaptive in Parkinson's disease (PD) patients suffering from dyskinesias, as compared to non-dyskinetic patients. Background:…Painful Legs and Moving Toes (PLMT): A Case Series
Objective: Describe and characterize our PLMT patients in terms of clinical presentation, neurophysiology, imaging, associated conditions and response to treatment. Background: First described by Spillane…Effect of Levodopa-Carbidopa Intestinal Gel Versus Optimized Medical Treatment on Dyskinesia in Advanced Parkinson’s Disease Patients: Final Results of the Randomized 12-Week DYSCOVER Study
Objective: This study evaluated the effectiveness of LCIG versus optimized medical treatment (OMT) on the duration and severity of dyskinesia in aPD patients. Background: Approximately…The utility of single dose levodopa challenges in the management of Parkinson’s disease
Objective: To retrospectively review the clinical utility of single dose levodopa challenges in the management of Parkinson in a tertiary movement disorder clinic. Background: Acute…Ziconotide-Induced Orolingual Dyskinesia: A Case Series
Objective: Our aim is to report three cases of orolingual dyskinesia in adults receiving intrathecal ziconotide for chronic pain management. Background: Ziconotide (ZCN), a nonopioid…Safety and efficacy of istradefylline, an adenosine A2A receptor antagonist, as a function of baseline dyskinesia (BL-dyskinesia) in Parkinson’s disease (PD): A pooled analysis of 4 studies
Objective: To evaluate the effect of BL-dyskinesia on the efficacy and safety of istradefylline in 4 randomized, placebo-controlled, double-blind, phase 2b/3 trials. Background: Istradefylline, a…MDS Translation Program for MDS-UPDRS, UDysRS, and MDS-NMS
Objective: To summarize the status of the ongoing MDS-sponsored translation programs for non-English versions of the MDS-UPDRS, UDysRS, and MDS-NMS. Background: The MDS-UPDRS, UDysRS, and…Early-onset peak dose Levodopa induced dyskinesia in elderly Ethiopian Parkinson’s disease patient
Objective: The aim was to report an early onset peak dose dyskinesia in a 55 years old Parkinson's disease patient who was naive to treatment…
- « Previous Page
- 1
- …
- 13
- 14
- 15
- 16
- 17
- …
- 40
- Next Page »